These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 26614369

  • 1. Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors.
    Mulvey CK, Bergsland EK.
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):63-82. PubMed ID: 26614369
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Medical treatment of neuroendocrine tumours.
    Weber HC.
    Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
    [Abstract] [Full Text] [Related]

  • 4. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors.
    Narayanan S, Kunz PL.
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):163-77. PubMed ID: 26614375
    [Abstract] [Full Text] [Related]

  • 5. Evolving treatment strategies for management of carcinoid tumors.
    Strosberg J.
    Curr Treat Options Oncol; 2013 Sep; 14(3):374-88. PubMed ID: 23892588
    [Abstract] [Full Text] [Related]

  • 6. [Pharmacologic therapy for neuroendocrine tumours].
    Petrányi A, Bodoky G.
    Orv Hetil; 2011 Mar 06; 152(10):379-91. PubMed ID: 21354954
    [Abstract] [Full Text] [Related]

  • 7. [Molecular target therapy for gastroenteropancreatic neuroendocrine tumors].
    Inoue N, Komoto I, Awane M, Imamura M.
    Nihon Rinsho; 2012 Nov 06; 70 Suppl 8():492-5. PubMed ID: 23513889
    [No Abstract] [Full Text] [Related]

  • 8. Systemic therapy for advanced carcinoid tumors: where do we go from here?
    Paulson AS, Bergsland EK.
    J Natl Compr Canc Netw; 2012 Jun 01; 10(6):785-93. PubMed ID: 22679120
    [Abstract] [Full Text] [Related]

  • 9. [Carcinoid tumors].
    Pregun I, Bodoky G, Rácz K, Tulassay Z.
    Orv Hetil; 2010 Nov 14; 151(46):1885-94. PubMed ID: 21044939
    [Abstract] [Full Text] [Related]

  • 10. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
    Leung R, Lang B, Wong H, Chiu J, Yat WK, Shek T, Cho WY, Yau LC, Yau T.
    Anticancer Agents Med Chem; 2013 Mar 14; 13(3):382-8. PubMed ID: 23092266
    [Abstract] [Full Text] [Related]

  • 11. Gastroenteropancreatic neuroendocrine tumors: update on therapeutics.
    Ganetsky A, Bhatt V.
    Ann Pharmacother; 2012 Jun 14; 46(6):851-62. PubMed ID: 22589450
    [Abstract] [Full Text] [Related]

  • 12. Targeting the mTOR signaling pathway in neuroendocrine tumors.
    Chan J, Kulke M.
    Curr Treat Options Oncol; 2014 Sep 14; 15(3):365-79. PubMed ID: 25092520
    [Abstract] [Full Text] [Related]

  • 13. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors.
    Pavel ME, Wiedenmann B.
    Horm Metab Res; 2011 Nov 14; 43(12):844-53. PubMed ID: 22105475
    [Abstract] [Full Text] [Related]

  • 14. Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.
    Raj N, Reidy-Lagunes D.
    Pancreas; 2014 Nov 14; 43(8):1185-9. PubMed ID: 25333401
    [Abstract] [Full Text] [Related]

  • 15. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP.
    Gastroenterology; 2010 Sep 14; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [Abstract] [Full Text] [Related]

  • 16. Systemic treatment of neuroendocrine tumors with hepatic metastases.
    Demirkan BH, Eriksson B.
    Turk J Gastroenterol; 2012 Sep 14; 23(5):427-37. PubMed ID: 23161287
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of mTOR in carcinoid tumors.
    Grozinsky-Glasberg S, Pavel M.
    Target Oncol; 2012 Sep 14; 7(3):189-95. PubMed ID: 22886906
    [Abstract] [Full Text] [Related]

  • 18. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
    Boussaha T, Rougier P, Taieb J, Lepere C.
    Clin Res Hepatol Gastroenterol; 2013 Apr 14; 37(2):134-41. PubMed ID: 23562338
    [Abstract] [Full Text] [Related]

  • 19. Update on the management of neuroendocrine tumors: focus on somatostatin antitumor effects.
    Gardner-Roehnelt NM.
    Clin J Oncol Nurs; 2012 Feb 14; 16(1):56-64. PubMed ID: 22297008
    [Abstract] [Full Text] [Related]

  • 20. Systemic therapeutic options for carcinoid.
    Pavel M, Kidd M, Modlin I.
    Semin Oncol; 2013 Feb 14; 40(1):84-99. PubMed ID: 23391116
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.